- Home
- RAND vs BEAT Comparison
RAND vs BEAT Comparison
Compare RAND & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- BEAT
- Stock Information
- Founded
- RAND 1969
- BEAT 2015
- Country
- RAND United States
- BEAT United States
- Employees
- RAND N/A
- BEAT N/A
- Industry
- RAND Finance: Consumer Services
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- RAND Finance
- BEAT Technology
- Exchange
- RAND Nasdaq
- BEAT Nasdaq
- Market Cap
- RAND 80.9M
- BEAT 65.1M
- IPO Year
- RAND N/A
- BEAT 2021
- Fundamental
- Price
- RAND $28.10
- BEAT $2.08
- Analyst Decision
- RAND
- BEAT Buy
- Analyst Count
- RAND 0
- BEAT 1
- Target Price
- RAND N/A
- BEAT $8.00
- AVG Volume (30 Days)
- RAND 17.6K
- BEAT 132.5K
- Earning Date
- RAND 03-04-2025
- BEAT 03-19-2025
- Dividend Yield
- RAND 17.90%
- BEAT N/A
- EPS Growth
- RAND 123.39
- BEAT N/A
- EPS
- RAND 4.98
- BEAT N/A
- Revenue
- RAND $8,351,941.00
- BEAT N/A
- Revenue This Year
- RAND N/A
- BEAT N/A
- Revenue Next Year
- RAND N/A
- BEAT N/A
- P/E Ratio
- RAND $5.64
- BEAT N/A
- Revenue Growth
- RAND 16.96
- BEAT N/A
- 52 Week Low
- RAND $13.69
- BEAT $1.35
- 52 Week High
- RAND $31.89
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- RAND 78.59
- BEAT 39.34
- Support Level
- RAND $22.77
- BEAT $2.05
- Resistance Level
- RAND $28.00
- BEAT $2.37
- Average True Range (ATR)
- RAND 1.67
- BEAT 0.18
- MACD
- RAND 0.42
- BEAT -0.02
- Stochastic Oscillator
- RAND 61.64
- BEAT 21.24
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.